4 results
To determine the efficacy endpoint whether the lack of ATP function will cause more appropriate but unnecessary shock therapy in patients with a S-ICD. Furthermore we will study the complication endpoint whether the S-ICD is superior to the TV-ICD…
The primary objectives are to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RP2D) of ABBV-621 and to evaluate pharmacokinetics (PK) of (A) single agent ABBV-621; and (B) the combination of ABBV-621 and venetoclax in…
To establish that recovery time from a bronchoprofocation test is faster with HFNC compared to no interfention
The primary objective is to develop and validate non-invasive portal pressure measurement by MRI in patients with end-stage liverdisease (ESLD).